Key Takeaways
- • Kamada Ltd. (NASDAQ: KMDA) secured a three-year agreement to supply normal source plasma to an unnamed biopharmaceutical company, generating approximately $50 million in total revenue over the contract period.
- • Commercial sales under the agreement are expected to commence in Q4 2026 and are already incorporated into Kamada's full-year revenue guidance, with the company reporting $181.7 million in trailing twelve-month revenue and 8.6% growth.
- • The deal supports Kamada's vertical-integration strategy and multi-year revenue growth objectives, leveraging its FDA-approved plasma collection centers in Houston and San Antonio, Texas, each designed for approximately 50,000 liters annual capacity.
- • Benchmark maintained a Buy rating on Kamada stock in connection with the plasma deal announcement, reflecting analyst confidence in the company's growth trajectory and deal execution.
- • Kamada operates three FDA-approved plasma collection centers in Texas (Beaumont, Houston, and San Antonio) and markets six FDA-approved specialty plasma-derived products.
Summary
Kamada Ltd., a biopharmaceutical company specializing in plasma-derived therapies, announced a three-year plasma supply agreement expected to generate approximately $50 million in revenue over the contract term. The agreement covers the supply of normal source plasma from Kamada's FDA-approved collection centers located in Houston and San Antonio, Texas. The company expects to record initial commercial sales from this agreement in the fourth quarter of 2026, and these sales have been incorporated into the company's existing full-year revenue guidance, indicating management confidence in timely execution.
According to Amir London, Chief Executive Officer, the agreement "supports both our vertical-integration strategy, as well as our multi-year revenue growth objectives." This characterization suggests the deal represents more than transactional revenue; it reinforces Kamada's broader business model of controlling plasma supply chains while expanding commercial relationships with biopharmaceutical customers. The company reported trailing twelve-month revenue of $181.7 million with 8.6% year-over-year growth, providing context for the $50 million three-year contract's significance to overall revenue trajectory.
Kamada's plasma collection infrastructure comprises three FDA-approved facilities in Texas, with each center designed to support approximately 50,000 liters of annual capacity at full operational capacity. The facilities collect both normal source plasma and specialty plasma products, positioning the company to serve diverse customer requirements across the biopharmaceutical sector. The company's product portfolio includes six FDA-approved specialty plasma-derived therapies, establishing it as an integrated player spanning collection, manufacturing, and commercial operations.
Benchmark maintained a Buy rating on Kamada stock in connection with the announcement, signaling analyst support for the company's strategic direction and growth prospects. The timing of the deal announcement and its integration into existing guidance demonstrates management's ability to execute on anticipated revenue streams while maintaining visibility with the investment community.
According to Amir London, Chief Executive Officer, the agreement "supports both our vertical-integration strategy, as well as our multi-year revenue growth objectives." This characterization suggests the deal represents more than transactional revenue; it reinforces Kamada's broader business model of controlling plasma supply chains while expanding commercial relationships with biopharmaceutical customers. The company reported trailing twelve-month revenue of $181.7 million with 8.6% year-over-year growth, providing context for the $50 million three-year contract's significance to overall revenue trajectory.
Kamada's plasma collection infrastructure comprises three FDA-approved facilities in Texas, with each center designed to support approximately 50,000 liters of annual capacity at full operational capacity. The facilities collect both normal source plasma and specialty plasma products, positioning the company to serve diverse customer requirements across the biopharmaceutical sector. The company's product portfolio includes six FDA-approved specialty plasma-derived therapies, establishing it as an integrated player spanning collection, manufacturing, and commercial operations.
Benchmark maintained a Buy rating on Kamada stock in connection with the announcement, signaling analyst support for the company's strategic direction and growth prospects. The timing of the deal announcement and its integration into existing guidance demonstrates management's ability to execute on anticipated revenue streams while maintaining visibility with the investment community.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.